-
3 Pathology and Diagnostics Network, Healthcare Technology and Services Company and Formulations and Ingredients Maker Stocks With a Strong Future Roadmap: Metropolis Healthcare, Indegene and Ipca Laboratories
- November 4, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
No Comments
Pathology, Health Tech and Drug Stocks with a strong future roadmap: Metropolis Healthcare, Indegene and Ipca Laboratories. Compare price, valuation, return on equity and revenue growth as of 3 November 2026.
-
3 Multi Speciality Hospital Chain, Pathology and Diagnostics Company and Largest Pharma Company Stocks With a Strong Future Roadmap: Max Healthcare Institute, Metropolis Healthcare and Sun Pharma
- October 30, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Hospital, Pathology and Pharma Leader Stocks with a strong future roadmap: Max Healthcare Institute, Metropolis Healthcare and Sun Pharma. Compare price, valuation, return on equity and revenue growth as of 28 October 2026.
-
3 Molecular Testing Company, National Pathology Network and Public Partnership Diagnostics Provider Stocks With a Strong Future Roadmap: Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics
- October 29, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Molecular Testing and Pathology Lab Stocks with a strong future roadmap: Molbio Diagnostics, Metropolis Healthcare and Krsnaa Diagnostics. Compare price, valuation, return on equity and revenue growth as of 28 October 2026.
-
3 Maternity and Critical Care Hospital Operator, Single-Use Devices Exporter and National Diagnostics Chain Stocks With a Strong Future Roadmap: Jupiter Life Line Hospitals, Poly Medicure and Metropolis Healthcare
- October 26, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Hospital, Medical Device and Diagnostics Stocks with a strong future roadmap: Jupiter Life Line Hospitals, Poly Medicure and Metropolis Healthcare. Compare price, valuation, return on equity and revenue growth as of 23 October 2026.
-
3 Largest Private Hospital Group, Regional Hospital Network and National Pathology Chain Stocks With a Strong Future Roadmap: Apollo Hospitals Enterprise, Krishna Institute of Medical Sciences and Metropolis Healthcare
- October 23, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Private Hospital and Pathology Services Stocks with a strong future roadmap: Apollo Hospitals Enterprise, Krishna Institute of Medical Sciences and Metropolis Healthcare. Compare price, valuation, return on equity and revenue growth as of 22 October 2026.
-
3 Paediatric Hospitals, Pathology Network and Multi-Specialty Care Stocks With a Strong Future Roadmap: Rainbow Children’s Medicare, Metropolis Healthcare and Fortis Healthcare
- October 22, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Paediatric Care and Diagnostics Stocks with a strong future roadmap: Rainbow Children’s Medicare, Metropolis Healthcare and Fortis Healthcare. Compare price, valuation, return on equity and revenue growth as of 21 October 2026.
-
3 Tertiary Care Campus, Heart Care Network and Diagnostic Labs Stocks With a Strong Future Roadmap: Global Health, Narayana Hrudayalaya and Metropolis Healthcare
- October 21, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Healthcare Delivery Stocks with a strong future roadmap: Global Health, Narayana Hrudayalaya and Metropolis Healthcare. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.
-
3 Diagnostic Stocks With a Strong Future Roadmap: Dr. Lal PathLabs, Metropolis Healthcare and Vijaya Diagnostic Centre
- October 6, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Dr. Lal PathLabs, Metropolis Healthcare and Vijaya Diagnostic Centre compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.
-
Buy, Sell Or Hold: Dr Lal PathLabs, Metropolis Healthcare, Poly Medicure, Vijaya Diagnostic Centre, Syngene International — Analyst Forecast
- September 28, 2026
- Posted by: Ankit Jaiswal
- Category: Market
A look at 5 healthcare stocks in India, Dr Lal PathLabs, Metropolis Healthcare, Poly Medicure, Vijaya Diagnostic Centre and Syngene International, with a buy, hold or sell view on each.
-
Metropolis Healthcare Q2 Results: Can the Volume-Led Growth Streak Continue?
- September 24, 2026
- Posted by: Kunal Singla
- Category: Market
Metropolis Healthcare Q2 FY27 results date is unconfirmed; Q1 FY27 profit rose 26% YoY on volume-led growth, achieved without any price hikes.